An Open-label, Parallel-group, Randomized, Multicenter Study to Assess the Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids Versus Standard of Care
Latest Information Update: 29 Aug 2024
At a glance
- Drugs Vilaprisan (Primary)
- Indications Uterine leiomyoma
- Focus Pharmacodynamics; Registrational
- Acronyms ASTEROID 6
- Sponsors Bayer
- 27 Aug 2024 Status changed from completed to discontinued.
- 24 Dec 2021 Trial has been completed in Finland.
- 23 Nov 2021 Planned End Date changed from 29 Oct 2021 to 30 Jun 2024.